Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 5/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 5/20 | 0.41 |
| ▸ | PREP | P48147 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18426928 | 1.00 | KCNK3 (0.41) | KCNK3KCNK9PREPCHRM2CHRM1 | |
| SCHEMBL16062559 | 1.00 | KCNK3 (0.41) | KCNK3KCNK9PREPCHRM2CHRM1 | |
| SCHEMBL17066303 | 0.94 | PREP (0.42) | KCNK3KCNK9PREPCHRM2CHRM1 | |
| SCHEMBL12436385 | 0.94 | PREP (0.42) | KCNK3KCNK9PREPCHRM2CHRM1 | |
| SCHEMBL16062569 | 0.91 | PREP (0.40) | KCNK3KCNK9PREPCHRM2CHRM1 | |
| SCHEMBL12436556 | 0.90 | PREP (0.41) | PREPCHRM2CHRM1CHRM3KAT2B | |
| SCHEMBL12436928 | 0.90 | PREP (0.41) | PREPCHRM2CHRM1CHRM3KAT2B | |
| SCHEMBL12436927 | 0.88 | PREP (0.41) | PREPCHRM2CHRM1CHRM3KAT2B | |
| SCHEMBL16020769 | 0.85 | PREP (0.37) | PREPCHRM2CHRM1CHRM3KAT2B | |
| SCHEMBL16020770 | 0.85 | PREP (0.37) | PREPCHRM2CHRM1CHRM3KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2850072-B1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9365549-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-06-14 | — | — | US | disclosed |
| US-9156818-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156818-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150252023-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-10 | — | — | US | disclosed |
| US-9066944-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130287731-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-10-31 | — | — | US | disclosed |
| WO-2011031904-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130287731-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HCCS | KCNK3 4296/4885KCNK9 4620/4885PREP 1030/4885 |
| US-20150252023-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HCCS | KCNK3 4296/4885KCNK9 4620/4885PREP 1030/4885 |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | KCNK3 4258/4885KCNK9 4648/4885PREP 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.